Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID combined with IPH 2101
Innate Pharma announced that Celgene Corporationhas agreed to collaborate with Innate Pharma to evaluate the potential clinical synergy of the combination treatment regimen of lenalidomide (REVLIMID®) plus IPH 2101 in patients with multiple myeloma (“MMy”) who have failed first-line therapy. The companies will collaborate on the design of the trial and Celgene will provide supplies of lenalidomide.
Lenalidomide is an immuno-modulatory drug that works through multiple mechanisms of action affecting tumor cells and their microenvironment including the immune cellular system. It has been demonstrated that lenalidomide also activates NK cells (Hayashi et al. 2005, Reddy et al. 2007). Since IPH 2101 potentiates NK cells’ anti-tumor activity, it is expected that lenalidomide and IPH 2101 should have a synergistic effect. This synergy has been documented in vitro on multiple myeloma cell lines (Zhu et al. 2008) and the planned Phase II clinical trial will aim to assess this synergy in patients with multiple myeloma.
The trial will be conducted in the USA. The Investigational New Drug (“IND”) application should be submitted in early 2010 by Innate Pharma. The objectives of the trial will be to assess tolerance, efficacy and various pharmacodynamic aspects with the combination. Further details on the trial will be given upon IND clearance by the FDA.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
